Endocrine-responsive breast cancer special types: who cares?
So, who actually cares about endocrine-responsive special types? At least the expert panel of the St Gallen consensus does [1] . Their recommendations for systemic treatment made in March 2011 were based on six subtypes; five from a simplified version of the intrinsic biological classification [2] and the sixth combining 'special histological types'. This last group represents up to 25% of all breast cancers [3] and can be subdivided into an endocrine-responsive group and an endocrine-non-responsive group. The publication from the European Institute of Oncology (EIO) of Milan published in this issue of the journal concentrates on a large series of endocrine-responsive tumours [4] . This publication has many strengths. It presents a large series of 1665 special-type cancers, out of 7372 invasive ductal luminal breast cancers accrued in a single institution, over a short period of time (9 years), and with 5.8 years of follow-up. All cases were re-evaluated independently by two of the pathologists and the criteria used to define the special types are provided in the publication. A detailed description of systemic adjuvant treatment is provided. Based on these strengths, this publication brings important data on the associations between special types and prognosis.
The EIO series confirms the excellent prognosis of two special types, the tubular and cribriform types, accounting for 4.5% of all luminal breast cancers (333/7372), with a 5-year disease-free survival for the pooled analysis of these two groups of 98.7% compared with 87.4% for invasive ductal carcinoma (IDC). This group (n = 83) confirms the excellent prognosis of tubular carcinoma previously reported, e.g. in a recently published series of 102 tubular carcinomas from a single institution (the Nottingham series) with long follow-up [5] . In this series, none of the patients with a tubular carcinoma developed distant metastasis. The only discordant series that reported no differences between tubular carcinoma and grade 1 IDC was from a cancer registry database without central pathology review [6] . Regarding the cribriform group in the EIO series (n = 250), 22 tumours were T2, 48 presented with nodal involvement and 6 were HER2 positive. Interestingly, the authors divided this special type according to two immunohistochemically defined tumour subtypes, luminal A and B. Although 24% (59/250) of cribriform carcinomas were classified as luminal B cancers, their prognosis remained excellent ( Figure 1 , panel luminal B). This excellent prognosis remains in the multivariate analysis with hazard ratios (HRs) of 0.48, 0.35 and 0.57 for disease-free, distant metastasis-free and overall survivals, respectively. Lastly, 8% of patients (28/333) in these two types received adjuvant chemotherapy, the benefit of which is certainly questionable (Table 3) .
Good prognosis of pure mucinous breast cancers is generally reported in the literature [7] . In a large retrospective series of 11 400 pure mucinous cancers from the SEER database between 1973 and 2002, breast cancer-specific survival of this special type was better than for IDC [7] . However, in the EIO series (n = 143), these tumours have similar disease-free and overall survivals as IDC [4] . A first explanation for this apparent discordance might just be a statistical chance and it should be emphasized that the 95% confidence intervals (CIs) in the EIO series are wide. In addition, disease-free and overall survivals may not be the best outcome measures. Breast cancer-specific and distant metastasis-free survivals could be more relevant to the discussion. Distant metastasis-free survival is provided in the EIO series (Table 4 ) and the risk of distant metastasis is approximately halved in the mucinous group compared with the IDC (HR 0.54; 95% CI 0.20-1.46). Another explanation for this apparently conflicting result could be the heterogeneity within the pure mucinous type. A recent genomic analysis using high-resolution microarray-based comparative genomic hybridization of a series of mucinous breast cancers compared with IDC showed that pure mucinous types cluster together on unsupervised analysis [8] . However, despite this apparent 'homogeneity', important differences remain between individual mucinous tumours both at a genomic [8] and a transcriptomic level [9] . Further studies are needed.
Invasive lobular carcinoma (ILC) is the most frequent special type and 851 cases are included in the EIO series [4] . Perhaps, one of the most interesting findings in this series is the association between lobular histology and poorer disease-free, distant metastasis-free and overall survivals, when compared with IDC in the univariate and multivariate analyses. Conflicting results are reported in the literature concerning the prognostic effects of lobular histology (full references are provided in the EIO publication) [4] . In one of the largest series, 767 cases of ILC were included in the context of a combined analysis of 15 International Breast Cancer Study Group (IBCSG) trials that accrued 9374 patients categorized as either pure IDC or ILC. The median follow-up was 13 years. In this publication, a significant time-dependent survival was observed with an early advantage in the ILC group and a late survival advantage in the IDC group [10] . In contrast, in the EIO series, there is a survival disadvantage for the ILCs with 5.8 years median follow-up. An important difference between these two series is that in the IBCSG series, 2700 estrogen-negative IDCs were included, which should have had an impact on early recurrences. Colleoni et al. [4] propose that the shorter survival observed might be explained by a possible 'under-treatment' of the ILC patients, who were more frequently offered endocrine therapy alone (anthracycline-containing chemotherapy was proposed in 26.7% of IDC and 18.6% of ILC). However, it should be acknowledged that the efficacy of chemotherapy in classic ILCs is still controversial (with the exception of a small subset of ILCs named pleomorphic variants that are grade III and are therefore candidates for cytotoxic therapy). In a retrospective analysis of six series of nearly 3000 patients including 354 ILCs treated with neoadjuvant chemotherapy, the pathological complete response rate is 1.7% in ILCs and 11.6% in IDCs [11] . In the adjuvant setting, a minority of randomized trials selected in a recent review on ILCs [11] mentioned the inclusion of this special type in the demographic sections and the histology has never been taken into consideration in the Oxford overviews [12] . At the risk of repeating what others have already said, prospective trials addressing the question of chemosensitivity in this special type should be a research priority.
As far as molecular biology is concerned, recently conducted studies have confirmed that ILCs are not just morphological variants of IDCs. Researchers compared the transcriptomic profile of ILCs and low-grade IDCs and found 270 transcripts to be differentially expressed, with CDH1 (Ecadherin) being down-regulated as shown in the majority of previous studies [13] . Interestingly, in this study when classic and pleomorphic lobular carcinomas were compared, only <0.1% of the transcripts were found to be differentially expressed. At a genomic level, a series of ILCs were analysed using complex CGH arrays and in situ hybridization [14] . An amplification on the 8p11.2-p12 region which encompasses the FGFR1 locus was frequently observed and might constitute a therapeutic target in selected ILCs. These results stress the importance of genomic characterization of special histological types of breast cancer. Many promising results have been published regarding endocrine non-responsive special types such as metaplastic, medullary, adenoid cystic and secretory carcinomas [15] . Additional preclinical research in endocrine-responsive special types, in particular ILCs, is needed to better understand the biology and to identify targets for therapy.
In conclusion, this important paper demonstrates that special types should be considered as part of therapeutic algorithms. Initially presented during the St Gallen 2011 meeting [16] , it has certainly influenced the expert recommendation established at this meeting [1] . This recommendation was made mainly because the identification of some of these subtypes is considered as a prognostic factor associated with excellent survival in endocrine-responsive tumours but also in endocrine non-responsive tumours which are not presented in this paper. We hope that in the near future ongoing laboratory research will identify specific targets in special types where survival cannot be qualified as excellent, e.g. for invasive lobular cancer, and that this may inspire clinical trials.
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